

AngioTox

Cancer Drug Toxicity

AngioTox will predict which patients are prone to cancer drug side effects

Clinically approved drugs which prevent blood vessel formation and thereby restrict blood flow to cancer cells can perform a vital role in blocking tumour growth and cancer spread. However, a major consequence of the recent progress in targeted medicine has been the toxic side effects which can occur as a result.

AngioTox aims to understand the mechanisms underlying toxicity that are associated with angiogenesis inhibitor drugs. The ultimate goal is to identify an *AngioTox* Safety Panel of toxicologic markers to facilitate improved screening of angiogenesis inhibitor toxicologic parameters, inform clinical drug dosing regimens, facilitate the development of more specific and potent angiogenesis inhibitors and significantly improve patient care.

SME Partners

OncoMark Ltd.



Bayer Technologies Services



Pathology Experts



Roche



Academic Partners

University College Dublin



Royal College of Surgeons
in Ireland (RCSI)



VU University Medical Centre



The *AngioTox* project received funding of just over €0.32 million under the Marie Curie Industry-Academia Partnerships and Pathways (IAPP). It was established in June 2010 to mechanistically assess the toxicities associated with the use of angiogenesis inhibitors for the treatment of cancer. It has four SME and three academic partners and will finish in June 2014.



AngioTox Tasks

- *AngioTox* will perform angiogenesis inhibitor safety studies in tumour-bearing animal models to comprehensively assess toxicologic patterns associated with angiogenesis inhibitor treatment, either alone or in combination with a standard chemotherapeutic.
- *AngioTox* will perform histopathologic assessment of tissues following treatment with angiogenesis inhibitors. Tissue microarrays (TMAs) will be prepared from each tissue for subsequent use in biomarker studies.
- *AngioTox* will investigate toxicologic mechanisms following angiogenesis inhibitor treatment. *AngioTox* will further attempt to identify a novel biomarker of bevacizumab- and antiangiogenic tyrosine kinase inhibitor-related toxicities in pre-clinical and clinical serum samples.

For more details on the project, please see the website www.angiotox.com

Dr. Máirín Rafferty, CEO of OncoMark Ltd., about the benefits of the *AngioTox* project for this SME:

"Understanding and developing tests for drug toxicity will allow OncoMark to support a very important range of cancer treatments."

If you have any questions or interested in more information, contact us at pr@oncomark.com

